Literature DB >> 32001193

Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.

Meghan Salcedo1, Nikoletta Lendvai1, Donna Mastey1, Julia Schlossman1, Malin Hultcrantz1, Neha Korde1, Sham Mailankody1, Alexander Lesokhin1, Hani Hassoun1, Eric Smith1, Urvi Shah1, Victoria Diab1, Kelly Werner1, Heather Landau2, Oscar Lahoud2, Pamela Drullinsky1, Gunjan Shah2, David Chung2, Michael Scordo2, Sergio Giralt2, Ola Landgren3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 32001193      PMCID： PMC7405911          DOI： 10.1016/j.clml.2019.12.013

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN： 2152-2669


× No keyword cloud information.
  3 in total

1.  Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.

Authors:  Nizar J Bahlis; Heather Sutherland; Darrell White; Michael Sebag; Suzanne Lentzsch; Rami Kotb; Christopher P Venner; Cristina Gasparetto; Aldo Del Col; Paola Neri; Donna Reece; Michael Kauffman; Sharon Shacham; T J Unger; Jacqueline Jeha; Jean-Richard Saint-Martin; Jatin Shah; Christine Chen
Journal:  Blood       Date:  2018-10-23       Impact factor: 22.113

2.  Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.

Authors:  Dan T Vogl; David Dingli; Robert Frank Cornell; Carol Ann Huff; Sundar Jagannath; Divaya Bhutani; Jeffrey Zonder; Rachid Baz; Ajay Nooka; Joshua Richter; Craig Cole; Ravi Vij; Andrzej Jakubowiak; Rafat Abonour; Gary Schiller; Terri L Parker; Luciano J Costa; David Kaminetzky; James E Hoffman; Andrew J Yee; Ajai Chari; David Siegel; Rafael Fonseca; Scott Van Wier; Gregory Ahmann; Ilsel Lopez; Michael Kauffman; Sharon Shacham; Jean-Richard Saint-Martin; Carla D Picklesimer; Cassandra Choe-Juliak; A Keith Stewart
Journal:  J Clin Oncol       Date:  2018-01-30       Impact factor: 44.544

3.  Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.

Authors:  Andrzej J Jakubowiak; Jagoda K Jasielec; Cara A Rosenbaum; Craig E Cole; Ajai Chari; Joseph Mikhael; Jennifer Nam; Amanda McIver; Erica Severson; Leonor A Stephens; Kathryn Tinari; Shaun Rosebeck; Todd M Zimmerman; Tyler Hycner; Agata Turowski; Theodore Karrison; Jeffrey A Zonder
Journal:  Br J Haematol       Date:  2019-05-24       Impact factor: 6.998
  3 in total
  2 in total

Review 1.  Safety and Efficacy Analysis of Selinexor-Based Treatment in Multiple Myeloma, a Meta-Analysis Based on Prospective Clinical Trials.

Authors:  Yali Tao; Hui Zhou; Ting Niu
Journal:  Front Pharmacol       Date:  2021-12-03       Impact factor: 5.810

2.  Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results.

Authors:  Holger W Auner; Sarah R Brown; Katrina Walker; Jessica Kendall; Bryony Dawkins; David Meads; Gareth J Morgan; Martin F Kaiser; Mark Cook; Sadie Roberts; Christopher Parrish; Gordon Cook
Journal:  Blood Cancer J       Date:  2022-04-01       Impact factor: 11.037
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.